Presentation (CTI)

OBJECTIVES: To assess the budgetary impact of introducing a biosimilar to omalizumab for the treatment of severe persistent allergic asthma, chronic spontaneous urticaria (CSU), and chronic rhinosinusitis with nasal polyps (CRSwNP) across 23 European countries from a payer’s perspective, and to estimate the potential number of additional patients who could be treated with the resulting cost savings.
METHODS: A biosimilar market share uptake-based budget impact model (BIM) was developed in Microsoft Excel to compare two scenarios over a 5-year horizon: one without biosimilar introduction and a scenario with and a scenario without biosimilars. Market share evolution was modeled using country-specific previously launched biosimilar uptake as a proxy, while omalizumab usage growth was estimated using historical compound annual growth rates. Drug acquisition costs were sourced from national price databases, assuming a 30% discount for the biosimilar. As the actual cost of reimbursement from the payer's perspective is known to be lower than 30%, a sensitivity analysis with a 50% and 70% reduction was also conducted.
RESULTS: The introduction of an omalizumab biosimilar is projected to yield first year savings of €41 million, when discounted at 30% in comparison to the scenario where originator is only marketed. 5-year cumulative savings are estimated at approximately €631 million and could enable treatment access for an estimated 118,460 additional patients. Sensitivity analysis applying 50% and 70% discount rates project first-year savings of €66 million and €92 million, respectively, and cumulative five-year savings range from €920 million to €1.41 billion. These savings could support access for an estimated 259,159 to 587,456 additional patients over five years.
CONCLUSIONS: Adopting an omalizumab biosimilar across European healthcare systems could lead to substantial cost savings, providing opportunities to expand patient access and alleviate fiscal pressure.